IGC Pharma, Inc.
IGC
$0.4658
$0.075819.44%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.95% | -5.50% | 1.64% | -11.98% | -15.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.95% | -5.50% | 1.64% | -11.98% | -15.38% |
| Cost of Revenue | 70.31% | 6.54% | 1.52% | -30.93% | -39.86% |
| Gross Profit | -4.84% | -15.55% | 1.76% | 11.95% | 15.50% |
| SG&A Expenses | -46.74% | -40.75% | -32.59% | -14.09% | -14.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.64% | -26.35% | -21.68% | -9.32% | -3.68% |
| Operating Income | 35.02% | 29.02% | 24.10% | 9.00% | 2.35% |
| Income Before Tax | 52.33% | 45.22% | 37.72% | -16.33% | -23.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.33% | 45.22% | 37.72% | -16.33% | -23.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.33% | 45.22% | 37.72% | -16.33% | -23.22% |
| EBIT | 35.02% | 29.02% | 24.10% | 9.00% | 2.35% |
| EBITDA | 36.78% | 30.70% | 25.47% | 9.48% | 2.44% |
| EPS Basic | 61.74% | 56.69% | 50.04% | 7.21% | -3.04% |
| Normalized Basic EPS | 52.17% | 46.46% | 40.14% | 27.59% | 17.16% |
| EPS Diluted | 61.74% | 56.69% | 50.04% | 7.21% | -3.04% |
| Normalized Diluted EPS | 52.17% | 46.46% | 40.14% | 27.59% | 17.16% |
| Average Basic Shares Outstanding | 23.98% | 30.04% | 29.68% | 29.64% | 20.66% |
| Average Diluted Shares Outstanding | 23.98% | 30.04% | 29.68% | 29.64% | 20.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |